School of Pharmacy, University of Reading, Whiteknights PO BOX 224 Reading RGD6 6AD Berkshire, UK.
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1203-13. doi: 10.1016/j.addr.2009.05.006. Epub 2009 Aug 20.
The discovery of new molecular targets and the subsequent development of novel anticancer agents are opening new possibilities for drug combination therapy as anticancer treatment. Polymer-drug conjugates are well established for the delivery of a single therapeutic agent, but only in very recent years their use has been extended to the delivery of multi-agent therapy. These early studies revealed the therapeutic potential of this application but raised new challenges (namely, drug loading and drugs ratio, characterisation, and development of suitable carriers) that need to be addressed for a successful optimisation of the system towards clinical applications.
新的分子靶点的发现和随后新型抗癌药物的开发为抗癌药物的联合治疗开辟了新的可能性。聚合物-药物偶联物已被广泛应用于单一治疗药物的递送，但直到最近几年，它们的应用才扩展到多药物联合治疗。这些早期的研究揭示了这种应用的治疗潜力，但也提出了新的挑战（即药物载药量和药物比例、药物性质鉴定以及合适载体的开发），这些挑战需要在系统向临床应用成功优化的过程中得到解决。
